Funding momentum OMRF is actively expanding its research infrastructure with significant federal and foundation support, including a $12.8M grant for the Center for Cellular Metabolism Research and a $500K grant from BrightFocus. This indicates strong grant-driven momentum and potential for partnerships around sponsored research, contract services, and technology licensing.

Strategic partnerships Recent grants and board additions signal openness to collaboration and governance engagement. Opportunities exist to engage with OMRF on joint research programs, clinical translation, and industry-aligned consortia that leverage their oncology, cardiovascular, autoimmune, and aging disease expertise.

High impact portfolio OMRF’s track record includes three FDA-approved drugs and first-in-class therapies, underscoring expertise in translational research, drug discovery, and target validation. Potential sales angles include access to translational platforms, assay development, biomarker discovery, and collaboration on preclinical development.

Talent and IP potential With a substantial workforce of 501-1000 and notable researchers like Jon Iker Etchegaray, OMRF represents a pool of expertise for collaborative grants, consulting, and joint venture projects. Consider engaging for sponsored research, technology transfer, and advisory services.

Public engagement and visibility OMRF’s discoveries attract broad media attention and academic recognition, including coverage in NEJM, Science, and major outlets. This visibility offers branding, co-development opportunities, and joint communications or educational programs that can enhance co-sponsored initiatives and grant proposals.